Bristol-Myers to acquire Celgene. Was this move really a surprise?

Bristol-Myers Squibb (BMY)   will acquire Celgene (CELG)  i n a cash and stock transaction with an equity value of approximately $74 billion . Under the terms of the agreement: Celgene shareholders wi...